article thumbnail

STAT+: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label

STAT

regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment.

Labelling 120
article thumbnail

STAT+: How digital therapeutics companies are improvising when insurance coverage isn’t guaranteed

STAT

Pear received Food and Drug Administration clearance for its app treating substance use disorders and insomnia but insurers mostly refused to cover the novel treatments. For years, the playbook for many companies that wanted to market digital therapeutics was stupid simple: Sell it like a prescription drug.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

4D Molecular’s Fabry gene therapy program on FDA clinical hold

Pharmaceutical Technology

4D Molecular Therapeutics (4DMT), the California-based biotechnology company focused on developing gene therapies for rare and large market diseases, has had the FDA place a clinical hold onto its Fabry disease (FD) gene therapy program (4D-310).

FDA 105
article thumbnail

FDA approves nasal spray to treat migraine

The Checkup by Singlecare

Other FDA-approved nasal sprays may have more side effects. Pricing, and subsequent information about insurance coverage, will be available at launch. The post FDA approves nasal spray to treat migraine appeared first on The Checkup. When will Zavzpret be available? In the U.S. In the U.S.

FDA 98
article thumbnail

FDA approves first drug to prevent Type 1 diabetes

The Checkup by Singlecare

Food and Drug Administration (FDA) approved the first drug to delay the onset of Type 1 diabetes. Tzield received priority review from the FDA, a status given to drugs with the potential for “significant improvement” in the treatment, diagnosis, or prevention of a serious condition. 17, the U.S.

FDA 98
article thumbnail

How much is Rexulti without insurance?

The Checkup by Singlecare

Without insurance coverage, Rexulti’s average price is around $1,926 for a 30-day supply. In August 2022, the FDA approved a generic version of brexpiprazole for schizophrenia as an adjunctive therapy to antidepressants for treating MDD. How much does Rexulti cost without insurance? What is the generic for Rexulti?

article thumbnail

STAT+: Wegovy reduces knee pain in osteoarthritis patients with obesity, study finds

STAT

  The results of the 68-week trial were published in the New England Journal of Medicine , and could pave the way for a future FDA approval of GLP-1 receptor agonists for the joint-degrading condition.  Continue to STAT+ to read the full story…